Bristol-Myers Squibb Co (BMY) Shares Sold by Boston Common Asset Management LLC

Boston Common Asset Management LLC lowered its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 8.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 90,149 shares of the biopharmaceutical company’s stock after selling 8,175 shares during the period. Boston Common Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $5,596,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Principal Financial Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 7.9% in the first quarter. Principal Financial Group Inc. now owns 3,094,134 shares of the biopharmaceutical company’s stock worth $195,704,000 after acquiring an additional 225,999 shares during the last quarter. IFM Investors Pty Ltd boosted its stake in shares of Bristol-Myers Squibb by 44.9% in the second quarter. IFM Investors Pty Ltd now owns 73,860 shares of the biopharmaceutical company’s stock worth $4,087,000 after acquiring an additional 22,871 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Fisher Asset Management LLC now owns 581,310 shares of the biopharmaceutical company’s stock worth $32,170,000 after acquiring an additional 4,229 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in shares of Bristol-Myers Squibb by 9.9% in the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 44,306 shares of the biopharmaceutical company’s stock worth $2,452,000 after acquiring an additional 4,000 shares during the last quarter. Finally, Peoples Financial Services CORP. boosted its stake in shares of Bristol-Myers Squibb by 17.8% in the second quarter. Peoples Financial Services CORP. now owns 39,768 shares of the biopharmaceutical company’s stock worth $2,200,000 after acquiring an additional 6,000 shares during the last quarter. 72.54% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently issued reports on the company. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $57.00 to $54.00 and set a “market perform” rating on the stock in a research note on Tuesday, October 23rd. Wolfe Research assumed coverage on Bristol-Myers Squibb in a research note on Tuesday, October 23rd. They issued an “outperform” rating and a $66.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, October 22nd. Citigroup lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $62.00 to $57.00 in a research note on Monday, October 22nd. Finally, ValuEngine lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Friday, October 19th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $62.42.

NYSE BMY opened at $50.69 on Monday. The firm has a market cap of $82.74 billion, a price-to-earnings ratio of 13.63, a P/E/G ratio of 1.41 and a beta of 1.08. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. Bristol-Myers Squibb Co has a fifty-two week low of $46.94 and a fifty-two week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Equities analysts anticipate that Bristol-Myers Squibb Co will post 3.87 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Stockholders of record on Friday, October 5th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.16%. The ex-dividend date was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 53.16%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: Stop Order Uses For Individual Investors

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply